世界睡眠医学杂志2026，Vol.13Issue(2)：265-268,4.DOI:10.3969/j.issn.2095-7130.2026.02.010
西格列汀辅助治疗阻塞性睡眠呼吸暂停综合征合并肥胖T2DM的效果
Effects of Sitagliptin as an Adjuvant Therapy for Obstructive Sleep Apnea-hypopnea Syndrome Complicated with Obesity and Type 2 Diabetes Mellitus
摘要
Abstract
Objective:To explore and analyze the effects of sitagliptin as an adjuvant therapy in patients with obstructive sleep apnea-hypopnea syndrome complicated with obesity and type 2 diabetes mellitus.Methods:A total of 120 patients with obstructive sleep apnea-hypopnea syndrome complicated with obesity and type 2 diabetes mellitus admitted to Huai'an Hospital Affiliated to Yangzhou University from January 1,2023 to January 31,2025 were selected as the study subjects.They were divided into the ob-servation group and the control group according to the random envelope drawing method,with 60 cases in each group.The control group received conventional treatment,while the observation group received sitagliptin treatment on the basis of the treatment in the control group.Both groups were treated and observed for 12 weeks,and the prognosis of the patients was recorded.Results:Af-ter treatment,the apnea-hypopnea index(AHI)in both groups was lower than that before treatment,and the AHI in the observa-tion group was lower than that in the control group after treatment,with statistically significant differences(P＜0.05).After treat-ment,fasting blood glucose(FBG)and 2-hour postprandial blood glucose(2 h PBG)in both groups were lower than those before treatment,and FBG and 2 h PBG in the observation group were significantly lower than those in the control group after treatment,with statistically significant differences(P＜0.05).After treatment,the body mass index(BMI)in both groups was lower than that before treatment,and the BMI in the observation group was significantly lower than that in the control group after treatment,with statistically significant differences(P＜0.05).There was no statistically significant difference in the incidence of adverse reactions such as hypoglycemia,gastrointestinal discomfort,headache,and respiratory tract infection between the observation group and the control group during treatment(P＞0.05).Conclusion:Sitagliptin as an adjuvant therapy for patients with obstructive sleep apne-a-hypopnea syndrome complicated with obesity and type 2 diabetes mellitus can reduce the apnea-hypopnea index,decrease fast-ing blood glucose and 2-hour postprandial blood glucose,and reduce body mass index,with good safety.关键词
西格列汀/阻塞性睡眠呼吸暂停综合征/肥胖/2型糖尿病/呼吸暂停低通气指数/安全性/血糖Key words
Sitagliptin/Obstructive sleep apnea-hypopnea syndrome/Obesity/Type 2 diabetes mellitus/Apnea-hypopnea in-dex/Safety/Blood glucose分类
医药卫生引用本文复制引用
杨春晓,徐跃,齐书静..西格列汀辅助治疗阻塞性睡眠呼吸暂停综合征合并肥胖T2DM的效果[J].世界睡眠医学杂志,2026,13(2):265-268,4.基金项目
江苏省基础研究计划项目(BK2023065). （BK2023065）
